Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Gains from Investment Securities (2016 - 2025)

Ligand Pharmaceuticals' Gains from Investment Securities history spans 16 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 12178.95% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, changed N/A, while the annual FY2025 figure was $2.3 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was $2.3 million at Ligand Pharmaceuticals, up from $6000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.2 million in Q2 2021 and bottomed at -$6.0 million in Q4 2022.
  • The 5-year median for Gains from Investment Securities is $13000.0 (2023), against an average of $639055.6.
  • The largest annual shift saw Gains from Investment Securities crashed 418.14% in 2021 before it soared 23561.54% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $3.3 million in 2021, then crashed by 283.2% to -$6.0 million in 2022, then increased by 28.71% to -$4.3 million in 2023, then skyrocketed by 99.56% to -$19000.0 in 2024, then skyrocketed by 12178.95% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Gains from Investment Securities are $2.3 million (Q4 2025), $6000.0 (Q3 2025), and -$786000.0 (Q2 2025).